Effects of Anthracycline Analogs on P-glycoprotein in Cancer Cells
Author Information
Author(s): E. Frichel, E.J.F. Demant, M. Sehested, N.I. Nissen
Primary Institution: Rigshospitalet-University Hospital
Hypothesis
Do anthracycline analogs inhibit P-glycoprotein and affect drug transport in multidrug resistant cells?
Conclusion
Certain anthracycline analogs significantly inhibit P-glycoprotein, enhancing drug accumulation in resistant cancer cells.
Supporting Evidence
- Vincristine inhibited P-glycoprotein labelling by 95%.
- N,N-dibenzyl-DNR and AD-198 showed the greatest inhibition of P-glycoprotein labelling.
- Increasing lipophilicity of anthracyclines correlated with their ability to inhibit P-glycoprotein.
- Cremophor EL and Tween 80 also inhibited P-glycoprotein labelling by over 90%.
Takeaway
Some cancer drugs can help other drugs work better by blocking a protein that pumps them out of cells.
Methodology
The study used photolabelling techniques to assess the inhibitory effects of anthracycline analogs on P-glycoprotein in resistant cancer cells.
Limitations
The study did not examine specific reversible binding or saturation experiments.
Participant Demographics
The study involved Ehrlich ascites tumor cells, both wild-type and daunorubicin-resistant.
Want to read the original?
Access the complete publication on the publisher's website